कंपनी का अवलोकन
Ginkgo Bioworks Holdings, Inc. operates as a developer of cell engineering platforms primarily within the United States, functioning through distinct Cell Engineering and Biosecurity segments to offer research and development solutions alongside specialized cell engineering tools. The corporation is categorized within the Healthcare sector and specifically the Biotechnology industry, which implies a focus on biological processes and therapeutic innovation rather than traditional manufacturing. In terms of scale, the company holds a market capitalization of $398.17M and generates an annual revenue of $170.16M while employing 485 individuals across its operations. These financial metrics indicate that Ginkgo Bioworks maintains a mid-cap valuation profile, suggesting a company that has established a revenue base but faces the challenges and capital requirements typical of the biotechnology sector where high research expenditures often constrain profitability despite significant market potential.
वित्तीय स्वास्थ्य
The company reported a revenue of $170.16M for the trailing twelve months, yet recorded a net income of $-312,763,008 and an EBITDA of $-267,822,000, a disparity that reveals a cost structure characterized by substantial operating expenses exceeding total revenue generation. The free cash flow stands at $-72,883,000, indicating that the company is burning cash from its operations and capital expenditures, which limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing. Analyzing the margins, the gross margin is 72.4%, reflecting efficient production costs relative to sales, whereas the operating margin is -209.7% and profit margin is -183.8%, signaling that operational and general administrative costs are disproportionately high compared to gross profits. Regarding liquidity and leverage, the company holds $422.62M in cash against $439.88M in debt, resulting in a debt-to-equity ratio of 86.49, which suggests a leveraged balance sheet where debt obligations nearly match available liquid assets. The current ratio is 4.92, a figure that indicates strong short-term liquidity and the ability to cover current liabilities with current assets more than four times over. Furthermore, the return on equity is -51.1% and the return on assets is -15.4%, metrics that reveal management effectiveness is currently negative, as the company's equity and asset base are generating losses rather than returns for shareholders.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to losses, while the forward P/E is -1.77, a difference that implies the market is pricing in future earnings expectations that do not yet reflect current profitability, often seen in growth-stage biotechnology firms. The price-to-book ratio is 0.74, indicating that the market values the company at 74% of its book value, which suggests the stock trades at a discount to the net asset value of its underlying equity. Alternative valuation metrics show a price-to-sales ratio of 2.34 and an EV/EBITDA of -1.46, figures that suggest the company is being valued based on revenue multiples rather than earnings power, a common practice for unprofitable entities with high growth potential. The 52-week high is $17.58 and the 52-week low is $5.37, placing the current implied trading context within a wide range where the stock exhibits significant volatility relative to its recent price history. The beta value is 1.57, meaning the stock price is expected to be 57% more volatile than the broader market, reflecting higher risk characteristics inherent to small-cap biotechnology stocks.
Growth & Income
The revenue growth year-over-year is -23.8%, while earnings growth is N/A due to the lack of positive net income, a situation where earnings cannot grow faster than revenue in the absence of profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available resources into research, development, and operational expansion rather than distributing cash to shareholders. Consequently, the overall growth and income profile for Ginkgo Bioworks Holdings, Inc. is defined by negative revenue expansion and a complete absence of dividend income, relying entirely on capital appreciation and operational turnaround for shareholder value creation. This strategic approach prioritizes long-term platform development and market penetration over immediate financial returns or income distribution to investors.